Pacific Biosciences of California (PACB) Stock Analysis & AI Equity Report
Pacific Biosciences of California (PACB) overview
Pacific Biosciences of California (PACB) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 160m and operating profit of USD -554m; the year-end share price was 1.87 USD and market capitalisation was USD 565m. Pacific Biosciences of California is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Pacific Biosciences of California's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Pacific Biosciences of California
Pacific Biosciences designs, develops, and manufactures sequencing systems and related products for genomic research. Its HiFi long-read technology supports studies of genomes, transcriptomes, and epigenomes across applications including human genetics, agriculture, infectious disease, microbiology, and oncology. Customers include research institutions, laboratories, genome centers, hospitals, clinical research organizations, pharmaceutical companies, and agricultural companies.
Generate the Pacific Biosciences of California report
Pacific Biosciences of California is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Pacific Biosciences of California and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Pacific Biosciences of California
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.